# MOTS-c Enters Phase 2a Human Trial for Prediabetes: What the Research Shows
A peptide your body already makes is now being tested in human clinical trials as a potential intervention for prediabetes — without drugs, without significant side effects, and with a mechanism that targets the root of metabolic dysfunction.
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) has quietly moved from animal research to Phase 2a human trials. The results being reported are drawing serious attention from researchers in metabolic medicine and longevity science.
What Is MOTS-c?
MOTS-c is a 16-amino acid peptide encoded not in your nuclear DNA, but in mitochondrial DNA. This makes it unusual: most peptides studied in research are produced from nuclear genes. MOTS-c originates from the 12S ribosomal RNA gene and is released from mitochondria into the bloodstream in response to metabolic stress.
Think of it as your mitochondria's distress signal — when energy production is inefficient, MOTS-c is released to orchestrate a whole-body metabolic recalibration.
First characterized by researchers at USC in 2015, MOTS-c was initially noted for its striking effects on aging and metabolic function in mice. The move to human trials in 2025 and 2026 represents a significant milestone.
The Prediabetes Problem
More than 98 million Americans have prediabetes — a state where blood glucose is elevated but not yet in the diabetic range. The standard medical approach is lifestyle intervention (diet, exercise) or metformin. Both have limitations:
- Lifestyle interventions require sustained behavioral change that most people struggle to maintain
- Metformin works but carries GI side effects and doesn't address the underlying mitochondrial dysfunction driving insulin resistance
MOTS-c targets something deeper: the mitochondrial inefficiency that precedes and drives insulin resistance.
Phase 2a Trial: What's Being Tested
The current Phase 2a trial is examining MOTS-c in adults with confirmed prediabetes (HbA1c 5.7–6.4%, fasting glucose 100–125 mg/dL). Key parameters being measured:
- Primary endpoint: Change in fasting glucose and HbA1c at 12 weeks
- Secondary endpoints: Insulin sensitivity (HOMA-IR), body composition, mitochondrial function markers, inflammatory cytokines (IL-6, CRP)
- Dosing: Subcutaneous injection, frequency determined by pilot pharmacokinetics
Early interim signals from the trial are encouraging:
- Participants showing improved insulin sensitivity without hypoglycemia risk
- Favorable tolerability profile — no severe adverse events reported in Phase 1
- Some participants demonstrating improved fat oxidation rates (measured via indirect calorimetry)
The Mechanism: How MOTS-c Works
Understanding MOTS-c's mechanism explains why it's being looked at for prediabetes specifically.
AMPK Activation
MOTS-c directly activates AMPK (AMP-activated protein kinase) — the master regulator of cellular energy balance. AMPK activation:
- Increases glucose uptake into muscle cells (insulin-independent pathway)
- Enhances fatty acid oxidation
- Reduces glucose production in the liver (hepatic gluconeogenesis)
- Improves mitochondrial biogenesis (your cells make more, healthier mitochondria)
This is the same pathway activated by exercise and metformin — but through an endogenous signaling molecule.
Folate Cycle Interference
MOTS-c also affects the folate and methionine cycles inside cells. When the cell's folate cycle is disrupted (which happens during metabolic stress), MOTS-c accumulates and moves from mitochondria to the nucleus, where it acts as a transcription regulator. This nuclear role enables MOTS-c to directly control gene expression related to metabolic adaptation.
Anti-Inflammatory Effect
Chronic low-grade inflammation is both a cause and consequence of insulin resistance. MOTS-c has demonstrated measurable reductions in:
- IL-6 (interleukin-6)
- TNF-α (tumor necrosis factor alpha)
- CRP (C-reactive protein)
In mouse models, these reductions correlated directly with improved glucose tolerance.
Skeletal Muscle Glucose Uptake
One of the most clinically relevant findings from animal studies: MOTS-c increases GLUT4 translocation to the cell surface in skeletal muscle. GLUT4 is the glucose transporter responsible for insulin-stimulated glucose uptake. Poor GLUT4 response is a primary driver of skeletal muscle insulin resistance. MOTS-c appears to enhance GLUT4 signaling even in the absence of insulin — a potentially powerful mechanism for reversing prediabetes.
Animal Data: The Foundation
The Phase 2a trial builds on a strong preclinical foundation.
2015 (Cell Metabolism): Original MOTS-c paper from USC. Showed that MOTS-c injection in mice prevented obesity, improved insulin sensitivity on high-fat diets, and extended metabolic health span.
2019 (Nature Communications): MOTS-c levels were found to naturally decline with age in mice and humans. Restoring MOTS-c in aged mice reversed age-related insulin resistance and improved physical performance.
